Overview
ABBV market data
Price History
ABBV price chart · 1M
- O
- 263.55
- H
- 263.79
- L
- 257.37
- C
- 260.19
- Vol
- 117,317.00
- Source
- US equities market feed
- Observed
- Sep 3, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $263.55
- Previous Close
- $261.68
- Day High
- $263.79
- Day Low
- $257.37
- 52 Week High
- $267.45
- 52 Week Low
- $198.77
- 7 Day Return
- +0.79%
- 30 Day Return
- +6.77%
- 90 Day Return
- +15.39%
- 1 Year Return
- +29.31%
- Daily Notional Volume
- $30.5M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 73.29 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $2.38 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.20 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 4.5% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 9.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $190.75 – $267.47 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $462.5B · P/B 94.44 · P/S 7.18.
Company News
10 captured
AbbVie Touts Positive Data For Multiple Myeloma DrugBenzinga · Sep 3, 2026, 6:10 PM
AbbVie Affirms FY2026 Adj EPS Guidance of $13.87-$14.07 vs $14.08 EstBenzinga · Sep 3, 2026, 1:17 PM
AbbVie Affirms Q3 Adj EPS Guidance of $3.84-$3.88 vs $3.84 EstBenzinga · Sep 3, 2026, 1:17 PM
Abbvie Announces Topline Results From The Phase 3 Cervino Trial Showing Etentamig Significantly Improved Response Rate And Progression-Free Survival In Patients With Relapsed/Refractory Multiple Myeloma; Etentamig Achieves 74% Orr And 60% Risk Reduction In Phase 3 Cervino Trial; Etentamig Demonstrates Low Rates Of Cytokine Release Syndrome And Fatal Infections; Phase 3 Cervino Study Met Dual Primary Endpoints; Full Results To Be Presented Sept 23-26Benzinga · Sep 3, 2026, 1:16 PM
8-K filing — AbbVie Inc. (ABBV)SEC EDGAR · Sep 3, 2026, 12:47 PM
AbbVie Anticipates Apogee Acquisition To Negatively Impact Adj Diluted EPS By $0.14 This Year, $0.46 In 2027, Accretion Beginning In 2032Benzinga · Sep 3, 2026, 12:46 PM
Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQThe Motley Fool · Sep 2, 2026, 5:15 PM
AZN Stock Down 20% in 6 Months: How to Play After Pipeline SetbacksZacks Investment Research · Sep 2, 2026, 4:30 PM
Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s?Zacks Investment Research · Sep 2, 2026, 4:30 PM
Vanguard Health Care ETF vs Simplify Health Care ETFThe Motley Fool · Sep 1, 2026, 8:15 PM